Annji Pharmaceutical Co., Ltd.

As of June 30, 2026, Annji Pharmaceutical Co., Ltd. carries a market capitalization of 5.90B, placing it among publicly traded companies globally. Its enterprise value stands at 5.49B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Annji Pharmaceutical Co., Ltd. has 100.94M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Annji Pharmaceutical Co., Ltd. maintains a current ratio of 3.58, meaning it holds 3.6x the short-term assets needed to cover near-term liabilities.

As of the close on October 22, 2026, Annji Pharmaceutical Co., Ltd.'s stock has gained approximately 53.02% over the past 52 weeks. The 50-day moving average sits at 64.99, while the 200-day moving average is 59.64.

As of June 30, 2026, Annji Pharmaceutical Co., Ltd. holds 460.27M in cash and equivalents against 46.30M in total debt, resulting in a net debt position of -456.26M. Total book value stands at 418.98M, with working capital of 354.04M providing operational flexibility.

Annji Pharmaceutical Co., Ltd.'s most recent stock split took place on February 23, 2026 with a 379:382 split ratio.